Evaluation of the HSE Naloxone Demonstration Project

Hdl Handle:
http://hdl.handle.net/10147/619155
Title:
Evaluation of the HSE Naloxone Demonstration Project
Authors:
Clarke, Ann; Eustace, Anne
Affiliation:
Eustace Patterson Ltd.
Citation:
Clarke, A, and Eustace, A. (2016) External Evaluation of the Naloxone Demonstration Project: Health Service Executive. 2016
Publisher:
Health Service Executive (HSE) National Social Inclusion Office
Issue Date:
31-Aug-2016
URI:
http://hdl.handle.net/10147/619155
Additional Links:
http://www.hse.ie
Item Type:
Report
Language:
en
Description:
Naloxone is a semi-synthetic competitive opioid antagonist medication recommended by the World Health Organisation (WHO) for the treatment of Opioid overdose. In 2014 the WHO released guidelines recommending that ‘People likely to witness an opioid overdose should have access to naloxone and be instructed in its administration to enable them to use it for the emergency management of suspected opioid overdose’. Ireland has one of the highest rates of drug overdose in Europe and in 2013 in 42% of deaths where heroin was implicated the individual was not alone when the drug was taken. This represents a situation where, in line with WHO recommendations, a specific intervention with Naloxone could have saved a life. The Naloxone Demonstration Project is therefore both a response to the WHO recommendations and also a response to Action 40 of the National Drugs Strategy (2009- 2016) aimed at tackling the harm caused by the misuse of drugs. This was also a key action of the 2015 HSE Primary Care, Social Inclusion operational plan.
Keywords:
DRUG; DRUGS MISUSE; DRUGS EDUCATION; OVERDOSE
Local subject classification:
NALOXONE

Full metadata record

DC FieldValue Language
dc.contributor.authorClarke, Annen
dc.contributor.authorEustace, Anneen
dc.date.accessioned2016-08-31T14:25:15Z-
dc.date.available2016-08-31T14:25:15Z-
dc.date.issued2016-08-31-
dc.identifier.citationClarke, A, and Eustace, A. (2016) External Evaluation of the Naloxone Demonstration Project: Health Service Executive. 2016en
dc.identifier.urihttp://hdl.handle.net/10147/619155-
dc.descriptionNaloxone is a semi-synthetic competitive opioid antagonist medication recommended by the World Health Organisation (WHO) for the treatment of Opioid overdose. In 2014 the WHO released guidelines recommending that ‘People likely to witness an opioid overdose should have access to naloxone and be instructed in its administration to enable them to use it for the emergency management of suspected opioid overdose’. Ireland has one of the highest rates of drug overdose in Europe and in 2013 in 42% of deaths where heroin was implicated the individual was not alone when the drug was taken. This represents a situation where, in line with WHO recommendations, a specific intervention with Naloxone could have saved a life. The Naloxone Demonstration Project is therefore both a response to the WHO recommendations and also a response to Action 40 of the National Drugs Strategy (2009- 2016) aimed at tackling the harm caused by the misuse of drugs. This was also a key action of the 2015 HSE Primary Care, Social Inclusion operational plan.en
dc.language.isoenen
dc.publisherHealth Service Executive (HSE) National Social Inclusion Officeen
dc.relation.urlhttp://www.hse.ieen
dc.subjectDRUGen
dc.subjectDRUGS MISUSEen
dc.subjectDRUGS EDUCATIONen
dc.subjectOVERDOSEen
dc.subject.otherNALOXONEen
dc.titleEvaluation of the HSE Naloxone Demonstration Projecten
dc.typeReporten
dc.contributor.departmentEustace Patterson Ltd.en
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.